DBV Technologies S.A.
DBV Technologies is a specialty biopharmaceutical company developing immunotherapies for food allergies and other immunological conditions. Its Viaskin platform delivers biologically active compounds, including allergens, through intact skin using an adhesive patch. The approach, called epicutaneous immunotherapy, is designed to expose immune cells in the skin to the allergen while limiting its passage into the bloodstream. The company’s lead product candidate is Viaskin Peanut Patch, which it is developing for children with peanut allergy, including separate programs for toddlers ages one to three and children ages four to seven. Other programs include Viaskin Milk Patch for cow’s milk allergy and eosinophilic esophagitis. DBV Technologies develops drug candidates through clinical trials and seeks regulatory approval to commercialize them. The company is headquartered in Chatillon.
No SEC Form 4 filings for $DBVT in the last 30 days.
See all $DBVT insider activity →DBV Technologies reported Q3 GAAP EPS of -$0.14, beating estimates by $0.07. The company posted operating income of $1.6M and had $165.7M in cash as of September 30, 2026, according to a press release.
DBV Technologies S.A. (DBVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Press Release Châtillon, France, October 28, 2026 DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update • Submitted the Biologics License Application to U.S. FDA for the VIASKIN ® Peanut Patch in children aged 4-7 Years and requested Prior
DBV Technologies reported $165.7M in cash as of Sept. 30, 2026, but anticipates needing more funding. The company submitted a BLA for its VIASKIN® Peanut Patch for children aged 4-7 to the FDA and requested Priority Review. DBV expects to need additional capital to sustain operations beyond 2027, with management exploring various financing options.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning DBVT (DBV Technologies S.A.). Coverage has been balanced: 2 bullish, 0 neutral, and 2 bearish.
Recent DBVT coverage spans corporate actions, earnings and regulation.
Earnings beat may lift the stock modestly.
The filing provides fresh financial data and a regulatory milestone, likely supporting a modest price uptick.
Funding shortfall creates near‑term downside risk.
The BLA filing could drive the stock higher if the FDA grants approval, but pending review adds uncertainty.
The BLA submission signals a potential regulatory approval that could unlock a new revenue stream.
AlphAI scores every news story that mentions DBVT with an AI model for sentiment and relevance, and aggregates insider trades from DBV Technologies S.A.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
DBV Technologies reported Q3 GAAP EPS of -$0.14, beating estimates by $0.07. The company posted operating income of $1.6M and had $165.7M in cash as of September 30, 2026, according to a press release.
1 min readDBV Technologies S.A. (DBVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Press Release Châtillon, France, October 28, 2026 DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update • Submitted the Biologics License Application to U.S. FDA for the VIASKIN ® Peanut Patch in children aged 4-7 Years and requested Prior
2 min readDBV Technologies reported $165.7M in cash as of Sept. 30, 2026, but anticipates needing more funding. The company submitted a BLA for its VIASKIN® Peanut Patch for children aged 4-7 to the FDA and requested Priority Review. DBV expects to need additional capital to sustain operations beyond 2027, with management exploring various financing options.
3 min readDBV Technologies S.A. (DBVT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN ® Peanut Patch in Children Aged 4-7 Years • The BLA is supported by the results from the successful Phase 3 VITESSE trial – the largest immunotherapy clinical trial to
2 min readDBV Technologies submitted a Biologics License Application to the FDA for its VIASKIN® Peanut Patch for children aged 4-7. The application is supported by positive Phase 3 trial results and seeks Priority Review. The patch uses epicutaneous immunotherapy to treat peanut allergies. DBV's shares trade on Euronext Paris and Nasdaq.
2 min readChâtillon, France, July 30, 2026 DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Capital Market: DBVT) (the "Company"), a late-stage biopharmaceutical company, today announced that, pursuant to the Company's At-The-Market Program established on September 1, 2025 and included in a new registration statement and accompanying prospectus filed on July 27, 2026, (the...
4 min readDBV Technologies (NASDAQ:DBVT) shares fell 3.7% after the company filed to refresh its at-the-market offering program, enabling sales of up to $150 million in American Depositary Shares. DBV said net proceeds would mainly fund manufacturing expansion, biologics license applications for ages 1 to 7, and launch prep for Viaskin Peanut (age 4 to 7), if approved.
3 min readDBV Technologies said it filed an automatically effective SEC Form S-3ASR shelf registration to refresh its at-the-market program for sales of up to $150 million of American Depositary Shares. The ADSs represent five ordinary shares and the program is under a Sept. 5, 2025 sales agreement with Citizens JMP Securities. Net proceeds would fund manufacturing expansion, BLAs, Viaskin Peanut launch prep, development, and working capital.
2 min readDBV Technologies S.A. (DBVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d156695dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Press Release Châtillon, France, July 16, 2026 DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update • Continued productive engagement with the FDA in support of the BLA for the VI
6 min readDBV Technologies (Euronext: DBV; Nasdaq: DBVT) published its half-year report on its AMF-regulated liquidity contract with ODDO BHF. Liquidity account assets rose from 41,159 shares and €432,367.25 (July 1, 2018) to 74,580 shares and €527,891.63 (Dec 31, 2025) and 146,321 shares and €396,088.22 (June 30, 2026). Jan 1–Jun 30, 2026: 1,989 buys and 2,012 sells; purchases 2,707,915 shares (€8.84m) and sales 2,636,174 shares (€8.70m).
2 min read
